Amundi’s Rhythm Pharmaceuticals RYTM Stock Holding History

Amundi’s Portfolio RYTM Stock Details RYTM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$380K	Sell	3,422 -595	-15%	-$53.8K	﹤0.01%	1750
2026 Q1	$349K	Buy	+4,017	New	+$391K	﹤0.01%	1686

Other funds holding RYTM

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Amundi's RYTM Position: Q2 2026 in Review

Amundi reduced its Rhythm Pharmaceuticals (RYTM) stake by 15% in Q2 2026, selling an estimated $53.8K and leaving 3,422 shares worth $380K. The position accounts for ﹤0.01% of the portfolio, ranked #1750.

Amundi first reported a position in RYTM in Q1 2026 and has held it in 2 quarters since. 303 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

Amundi held 3,422 shares of Rhythm Pharmaceuticals worth $380K as of Q2 2026.
Amundi sold 595 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $53.8K.
Rhythm Pharmaceuticals made up ﹤0.01% of Amundi's portfolio in Q2 2026, its #1750 holding.
Amundi first reported a position in Rhythm Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
303 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Amundi's 13F filing for Q2 2026, filed 11 Aug 2026.